The US FDA has proposed withdrawing Amgen's Tavneos after finding alleged clinical trial data manipulation. Regulators also report that untrue statements were made in the approval process for the drug ...
The US Food and Drug Administration (FDA) has just released its long-awaited Warning Letter to Sun Pharmaceuticals following a 483 and import alert announced earlier this year. And as the letter ...
The Food and Drug Administration's (FDA) drug review arm has proposed withdrawing approval for Amgen Inc.’s AMGN Tavneos (avacopan), citing concerns over data integrity, lack of proven effectiveness, ...
Morning Overview on MSN
FDA says "manipulated" data backed approval, moves to withdraw the drug
The FDA has moved to pull Tavneos (avacopan) from the U.S. market, alleging that manipulated clinical trial data propped up the drug’s 2021 approval for a rare and potentially fatal blood vessel ...
Compliance & Enforcement Team examines a new FDA compliance program for Center for Drug Evaluation and Research (CDER)-regulated ...
Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results. Amgen explained that ...
The EMA has started a review of Amgen Inc.’s Tavneos (avacopan) after questions were raised about the integrity of the data in the Advocate study that the agency assessed when granting approval of the ...
The warning letter, issued on March 30 following a September 2025 inspection, says the company’s manufacturing practices have failed to comply with good manufacturing norms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results